Home > Insider Trading > Filing (0001209191-18-007552)

Filing Details

Accession Number:: 0001209191-18-007552
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2018-02-05 16:57:24
Reporting Period:: 2018-02-01

Accepted Time:: 2018-02-05 16:57:24
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1652923	Avexis Inc.	AVXS	Biological Products, (No Disgnostic Substances) (2836)	901038273

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1665859	K. Brian Kaspar	C/O Avexis, Inc. 2275 Half Day Road, Suite 200 Bannockburn IL 60015	Chief Scientific Officer	Yes	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Disposition	2018-02-01	4,655	$117.05	1,792,147	No	4	S	Direct
Common Stock	Disposition	2018-02-01	7,218	$117.79	1,784,929	No	4	S	Direct
Common Stock	Disposition	2018-02-01	908	$118.67	1,784,021	No	4	S	Direct
Common Stock	Disposition	2018-02-01	993	$120.14	1,783,028	No	4	S	Direct
Common Stock	Disposition	2018-02-01	918	$121.17	1,782,110	No	4	S	Direct
Common Stock	Disposition	2018-02-01	208	$121.95	1,781,902	No	4	S	Direct
Common Stock	Disposition	2018-02-01	100	$122.83	1,781,802	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct

Footnotes

These sales were effected pursuant to a Rule 10b5-1 Sales Plan adopted by the Reporting Person on August 29, 2017.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $116.36 to $117.35, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (2) to this Form 4.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $117.36 to $118.33, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (3) to this Form 4.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $118.38 to $119.21, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (4) to this Form 4.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $119.66 to $120.58, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (5) to this Form 4.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $120.74 to $121.57, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (6) to this Form 4.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $121.79 to $122.24, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (7) to this Form 4.